A roundup of exits, including IPOs and acquisitions, across the tech transfer ecosystem.

The Global Corporate Venturing deal net rounds up the smaller investments from across the corporate innovation ecosystem.

The Takeda Vaccines spinoff floated in an upsized offering that granted its former parent $100m in shares.

Corporate-backed medical imaging technology producer Lunit is preparing to float in South Korea while cancer drug developer Pheast secured $76m from investors including Alexandria Venture Investments.

The Sinopharm-backed laboratory animal model developer floated on Shanghai Stock Exchange’s Star Market two years after its last equity funding.

The audio streaming service is set to list with help from a PIPE deal featuring Orange, Access Industries, Warner Music, UMG and Media Participations.

Tigermed, Fosun, Haisco and Sinopharm-CICC all scored exits as the oncology and metabolic disorder therapeutics went public in China.

The Takeda spinoff is developing a vaccine for acute gastroenteritis caused by norovirus infection, and raised about $140m in August 2021.

The gut microbiome drug developer went public in a $22.5m offering priced at the foot of its range.

The Macrogen-backed gut microbiome drug developer went public in a $22.5m offering priced at the foot of its range.